Recent News

• 04.14.2025 - Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)
• 04.14.2025 - Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)
• 04.02.2025 - Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
• 04.02.2025 - Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
• 03.12.2025 - Leerink Global Healthcare Conference
• 03.11.2025 - Barclays 27th Annual Global Healthcare Conference
• 03.05.2025 - Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
• 03.05.2025 - Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
• 03.04.2025 - Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
• 03.04.2025 - Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

• 04.07.2025 - PRE 14A Other preliminary proxy statements
• 03.06.2025 - 144 Report of proposed sale of securities
• 03.05.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.05.2025 - 8-K Current report
• 03.05.2025 - EX-99.1 EX-99.1